Research progress of biological targeted therapy for bronchial asthma / 国际生物医学工程杂志

ABSTRACT

Bronchial asthma (hereinafter referred to as asthma) is a chronic inflammatory disease of the airways composed of multiple cells (eosinophils, mast cells, T-lymphocytes, airway epithelial cells, etc.) and cellular components. Severe asthma is often recurrent and prolonged, and symptoms such as cough, chest tightness, shortness of breath, and wheezing are difficult to relieve, which seriously affects the patient's quality of life. At present, standard treatment with a combination of high-dose inhaled corticosteroids (ICS) and long-acting bronchodilators is recommended, but some patients still cannot be adequately controlled. This increases the patients' physical and mental burden and treatment costs. Asthma is a heterogeneous disease with multiple phenotypes, with wide variation in disease severity, type of airway inflammation, and therapeutic drugs, caused by a variety of pathophysiological mechanisms or endotypes. Individualized treatment for different individual pathogenesis in asthma patients is required, and targeted biological agents provide new hope for asthma patients. In this paper, the research progress of biological targeting agents in the treatment of asthma was reviewed.